Jump to content

Russell Dahl

Add links
From Wikipedia, the free encyclopedia
Russell Dahl
Born1974
NationalityAmerican
Alma materUniversity of California San Diego
Santa Clara University
Occupation(s)Organic chemist, academic and biotechnology entrepreneur

Russell Dahl (born 1974) is an American organic chemist, academic and biotechnology entrepreneur. Dahl is mainly known for his work in pharmaceutical research. He is the founder of biopharmaceutical startup Neurodon.

Life and career

[edit]

Dahl was raised in San Jose, California. He completed his undergraduate studies at Santa Clara University, graduating in 1997 with a bachelor's degree in chemistry and combined science.[1] In 2002, he obtained his master's degree in chemistry from the University of California San Diego (UCSD). Dahl earned his PhD in chemistry in 2004 from UCSD.[2][3] During his doctoral studies, Dahl had a fellowship at DuPont Pharmaceuticals where he and his team developed some of the first poly-ADP ribose polymerase (PARP) inhibitors for the treatment of cancers.[4][5] His thesis research at UCSD culminated in the development of new reaction methodology for the synthesis of biologically relevant oligosaccharides.[6][7][8]

From 2006 to 2012, he was the Director of Medicinal Chemistry Sanford-Burnham Medical Research Institute. Dahl has held faculty positions at University of Southern California, UC San Diego School of Medicine, Palomar College, Rosalind Franklin University of Medicine and Science, University of Illinois at Chicago, University of New England and Purdue University.[9][10]

His main area of work is pharmaceutical research and drug discovery. Most of his research is focused on the discovery and development of small molecules that inhibit ER stress-induced cell death and dysfunction, which plays a role in multiple diseases, including diabetes and neurodegenerative conditions. Dahl invented and patented small molecule activators of the sarco/endoplasmic reticulum Ca2+-ATPase,[11] or SERCA, a protein whose major function is to maintain calcium homeostasis in the cell.[12][13] One compound Dahl created, CDN1163, is utilized by researchers as a tool molecule to probe the effects of SERCA in various disease models.[14][15][16] Dahl has authored or co-authored over 100 peer-reviewed articles.[17][18]

During 2003 and 2006, Dahl discovered a series of alpha-ketoamides as selective inhibitors of the p38 mitogen-activated protein kinase that became drug candidates for inflammatory diseases.[19][20][21][22]

In 2015, Dahl founded Neurodon, a biopharmaceutical startup, with a focus on discovery of neuroprotective drugs for treatment of conditions such as diabetes, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).[23][24][25][26][27][28][29][30]

References

[edit]
  1. ^ "Russell Dahl". Santa Clara Magazine. Retrieved 2023-08-22.
  2. ^ "Chemistry Tree - Russell S. Dahl". academictree.org. Retrieved 2023-08-22.
  3. ^ "Russel Dahl - Biography".
  4. ^ "Learn More About Dr. Russel Dahl / His Role In Calcium ATPase Research". Brunde Broady. Retrieved 2023-08-22.
  5. ^ "Insights of Pharmacology and Pharmaceutical Science Editor Details". scholars.direct. Retrieved 2023-08-22.
  6. ^ Dahl, Russell S.; Finney, Nathaniel S. (2004-07-14). "A surprising dipolar cycloaddition provides ready access to aminoglycosides". Journal of the American Chemical Society. 126 (27): 8356–8357. doi:10.1021/ja0319238. ISSN 0002-7863. PMID 15237974.
  7. ^ Dahl, Russell; Baldridge, Kim K.; Finney, Nathaniel S. (July 2010). "Efficient Access to Aminomannoside Derivatives via Formal [2+2] Cycloaddition of Triazolinediones and Tri-O-acetyl-d-glucal". Synthesis. 2010 (13): 2292–2296. doi:10.1055/s-0029-1218803. ISSN 0039-7881.
  8. ^ Dahl, Russell S.; Finney, Nathaniel S. (2001-07-01). "Simple Glucal-Based Linker for the Immobilization of Alcohols on Solid Support". Journal of Combinatorial Chemistry. 3 (4): 329–331. doi:10.1021/cc0100058. ISSN 1520-4766. PMID 11442388.
  9. ^ "Russell Dahl". Santa Clara Magazine. Retrieved 2023-08-22.
  10. ^ "Science Prerequisites Faculty & Staff". UNE Online. Retrieved 2023-08-22.
  11. ^ "Google Patents". patents.google.com. Retrieved 2023-08-22.
  12. ^ Hovnanian, A. (2007), Carafoli, Ernesto; Brini, Marisa (eds.), "Serca pumps and human diseases", Calcium Signalling and Disease, Subcellular Biochemistry, vol. 45, Dordrecht: Springer Netherlands, pp. 337–363, doi:10.1007/978-1-4020-6191-2_12, ISBN 978-1-4020-6190-5, PMID 18193643, retrieved 2023-08-22
  13. ^ "Russell Dahl Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2023-08-22.
  14. ^ "Neurodon | Publications". Neurodon. Retrieved 2023-08-22.
  15. ^ Cornea, Razvan L.; Gruber, Simon J.; Lockamy, Elizabeth L.; Muretta, Joseph M.; Jin, Dongzhu; Chen, Jiqiu; Dahl, Russell; Bartfai, Tamas; Zsebo, Krisztina M.; Gillispie, Gregory D.; Thomas, David D. (January 2013). "High-throughput FRET assay yields allosteric SERCA activators". Journal of Biomolecular Screening. 18 (1): 97–107. doi:10.1177/1087057112456878. ISSN 1552-454X. PMC 3721969. PMID 22923787.
  16. ^ Gruber, Simon J.; Cornea, Razvan L.; Li, Ji; Peterson, Kurt C.; Schaaf, Tory M.; Gillispie, Gregory D.; Dahl, Russell; Zsebo, Krisztina M.; Robia, Seth L.; Thomas, David D. (February 2014). "Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells". Journal of Biomolecular Screening. 19 (2): 215–222. doi:10.1177/1087057113510740. ISSN 1552-454X. PMC 4013825. PMID 24436077.
  17. ^ "Russell Dahl". scholar.google.com. Retrieved 2023-08-22.
  18. ^ "Russell Dahl - CEO & Founder at Neurodon". THE ORG. Retrieved 2023-08-22.
  19. ^ Montalban, Antonio Garrido; Boman, Erik; Chang, Chau-Dung; Ceide, Susana Conde; Dahl, Russell; Dalesandro, David; Delaet, Nancy G. J.; Erb, Eric; Ernst, Justin T.; Gibbs, Andrew; Kahl, Jeffrey (2010-08-15). "Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site". Bioorganic & Medicinal Chemistry Letters. 20 (16): 4819–4824. doi:10.1016/j.bmcl.2010.06.102. ISSN 1464-3405. PMID 20663667.
  20. ^ Montalban, Antonio Garrido; Boman, Erik; Chang, Chau-Dung; Ceide, Susana Conde; Dahl, Russell; Dalesandro, David; Delaet, Nancy G. J.; Erb, Eric; Ernst, Justin; Gibbs, Andrew; Kahl, Jeffrey (2010-04-25). "KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase". European Journal of Pharmacology. 632 (1–3): 93–102. doi:10.1016/j.ejphar.2010.01.011. ISSN 1879-0712. PMID 20132813.
  21. ^ Montalban, Antonio Garrido; Boman, Erik; Chang, Chau-Dung; Ceide, Susana Conde; Dahl, Russell; Dalesandro, David; Delaet, Nancy G. J.; Erb, Eric; Gibbs, Andrew; Kahl, Jeff; Kessler, Linda (2008-10-15). "'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors". Bioorganic & Medicinal Chemistry Letters. 18 (20): 5456–5459. doi:10.1016/j.bmcl.2008.09.028. ISSN 1464-3405. PMID 18835164.
  22. ^ Montalban, Antonio Garrido; Boman, Erik; Chang, Chau-Dung; Ceide, Susana Conde; Dahl, Russell; Dalesandro, David; Delaet, Nancy G. J.; Erb, Eric; Ernst, Justin T.; Gibbs, Andrew; Kahl, Jeffrey (2008-03-15). "The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors". Bioorganic & Medicinal Chemistry Letters. 18 (6): 1772–1777. doi:10.1016/j.bmcl.2008.02.033. ISSN 1464-3405. PMID 18325768.
  23. ^ "Molecule could improve memory, reduce Alzheimer's degradation, study finds". ScienceDaily. Retrieved 2023-08-22.
  24. ^ Dahl, Russell; Moore, Amanda C.; Knight, Caitlynn; Mauger, Colleen; Zhang, Hua; Schiltz, Gary E.; Koss, Wendy A.; Bezprozvanny, Ilya (January 2023). "Positive Allosteric Modulator of SERCA Pump NDC-1173 Exerts Beneficial Effects in Mouse Model of Alzheimer's Disease". International Journal of Molecular Sciences. 24 (13): 11057. doi:10.3390/ijms241311057. ISSN 1422-0067. PMC 10341805. PMID 37446234.
  25. ^ Whooley, Sean (2021-05-17). "Neurodon prepping IND application for type 1 diabetes treatment". Drug Delivery Business. Retrieved 2023-08-22.
  26. ^ Foundation, Purdue Research (2022-07-07). "Take 6: Russell Dahl, Neurodon". The Line by PRF. Retrieved 2023-08-22.
  27. ^ Veleta, Kylie. "Startup awarded nearly $1M to advance diabetes drug". Inside INdiana Business. Retrieved 2023-08-22.
  28. ^ "Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)". www.businesswire.com. 2021-05-17. Retrieved 2023-08-22.
  29. ^ "Drug Discovery and Molecular Pharmacology B Study Section ROSTER". public.era.nih.gov. Retrieved 2023-08-22.
  30. ^ "NIA Small Business Showcase: Neurodon, LLC". National Institute on Aging. Retrieved 2023-08-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Russell_Dahl&oldid=1172506766"